15010 Broschart Road Suite 250. Rockville, Maryland, 20850, United States. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms Immunomic Therapeutics' nucleic acid vaccines have the . 2017 Apr 15;23(8):1898-1909. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. ITI-ID Candidate Multiple infectious diseases. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . ITI maintains its headquarters in Rockville, Maryland. Frans broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs, stated William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. All content is posted anonymously by employees working at Immunomic Therapeutics. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ITI-1001 is an alternative, cell-free approach to treating GBM. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. We provide a professional and challenging work environment . With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. Jan 2006 - Present17 years 2 months. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. 917-322-2571, Internet Explorer presents a security risk. Work Here? This is the Immunomic Therapeutics company profile. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. ITI maintains its headquarters in Rockville, Maryland. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. Founders Sungwuk Kim. Immunomic Therapeutics Announces Presentation on Nucleic Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs, Northeastern US Biotechnology Female Founded Companies. This feature is in beta and may change with future updates. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Phone Number +119196161923. Active, Closed, Last funding round type (e.g. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. immunomic therapeutics crunchbase. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. Very family oriented. Coordinates: 245831.9N 1213154.0E. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Company Type For Profit. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Announces Proposed Public Offering of Common Stock, Northeastern US Companies With Fewer Than 1000 Employees (Top 10K), Companies With Fewer Than 100 Employees (Top 10K), United States Companies that Exited (Top 10K), Greater New York Area Biotechnology Companies. Copied To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. J Biol Chem. ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Pays for all health and welfare insurance premiums 100%. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. ITI Company: ITI-3000 Merkel Cell Carcinoma - pDNA. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. 2003 Sep 26;278(39):37926-36. 2015 Mar 19;519(7543):366-9. J Immunol Res. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Hum Vaccin Immunother. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Clin Cancer Res. View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. All content is posted anonymously by employees working at Immunomic Therapeutics. November 30, 2021, 7:01 PM UTC. The financing will also enable Immunomic to expand its team and infrastructure to support the future growth of the company. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). ITI maintains its headquarters in Rockville, Maryland. The company was founded in 2005 and is based in Lancaster, Pennsylvania. Jan 30, 2015. You are here: hackberry allergy symptoms; 49ers paying players under the table; immunomic therapeutics crunchbase . We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. aanagnostou@immunomix.com We know that there are multiple aspects that inform our platform's success. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that, Vaccine exclusively delivered with the PharmaJet StratisNeedle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet, a company that engineers precision delivery systems that overcome, November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced, October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today. Senior Scientist/Scientist II, Formulation Development. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. SaaS, Android, Cloud Computing, Medical Device). Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . mkemp@immunomix.com They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Animal Health All. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI") a privately-held clinical-stage biotechnology company pioneering the . We are pleased to welcome HLB as a significant shareholder of Immunomic Therapeutics and look forward to working with them within the framework of the HLB Bio family of companies. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). ITI Company: This employer has not claimed their Employer Profile and is missing out on connecting with our community. ITI-1001 GBM - pDNA. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. J Immunol. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke.
Capital Region Urology Clifton Park,
Why Did Poshmark Delete My Closet,
30 The Market Place, London, Nw11 6jj,
How Much Did Muffy Win On The Chase,
Articles I